Duke logo

PVX-410 in Smoldering Multiple Myeloma (SMM) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how safe and comfortable PVX-410 in combination with CC-96241 (with and without lenalidomide) is for patients with smoldering multiple myeloma (SMM).

What is the Condition Being Studied?

Smoldering Multiple Myeloma

Patients determined to be eligible, based on Screening assessments, will be enrolled in the study.

Who Can Participate in the Study?

Diagnosis of Smoldering Multiple Myeloma

Age Group
Adults

What is Involved?

First, we will ask for a blood sample to determine eligibility.

If still eligible you will be asked to:
-Take the study drug as directed
-Complete blood draws
-Give a bone marrow sample
-A body scan (MRI, CT, X-ray)

Study Details

Full Title
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB:PRO00100313
NCT:NCT02886065
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698